AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.

Abstract # 3856 - Title: "A highly selective Erk-inhibitor with antiproliferative efficacy and the potential for combination therapy with modulators of the PI3K pathway", I. Seipelt, L. Blumenstein, S. Baasner, G. Mueller, B. Aicher, M. Teifel, E. Guenther, M. Gerlach. Oral Presentation: Session ID: Experimental and Molecular Therapeutics 29 Tuesday, April 20, 2010, 10:30 AM - 1:00 PM Abstract # 4474 - Title: "Dual inhibitors for PI3K and Erk induce growth inhibition of tumor cells", I. Seipelt, M. Gerlach, S. Baasner, L. Blumenstein, G. Mueller, B. Aicher, E. Guenther, M.l Teifel. Poster Presentation: Session ID: Experimental and Molecular Therapeutics 33 Location: Exhibit Hall A-C, Poster Section 24 Tuesday, April 20, 2010, 2:00 PM - 5:00 PM

Irene Seipelt, Ph.D., Associate Director, Drug Discovery & Preclinical Development at Æterna Zentaris, will make both presentations.

Copies of the abstracts are currently available and can be viewed on-line through the AACR 2010 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/abstracts.aspx.